Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
ADC Therapeutics SA | Chief Executive Officer, Director | Common Shares | 1.17M | $5.23M | $4.48 | May 7, 2024 | Direct |
Atara Biotherapeutics, Inc. | Director | Common Stock | 228K | $164K | $0.72 | Mar 31, 2024 | Direct |
Atara Biotherapeutics, Inc. | Director | Non-Qualified Stock Option (Right to Buy) | 79.5K | May 31, 2023 | Direct | ||
Rafael Holdings, Inc. | Director | Class B Common Stock, par value $.01 per share | 0 | $1.81 | Feb 1, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ADCT | ADC Therapeutics SA | May 7, 2024 | 1 | -$133K | 4 | May 9, 2024 | Chief Executive Officer, Director |
ATRA | Atara Biotherapeutics, Inc. | Mar 31, 2024 | 1 | $0 | 4 | Apr 2, 2024 | Director |
ADCT | ADC Therapeutics SA | Jan 2, 2024 | 0 | $0 | 3 | Jan 2, 2024 | Chief Executive Officer, Director |
ATRA | Atara Biotherapeutics, Inc. | May 31, 2023 | 2 | $0 | 4 | Jun 2, 2023 | Director |
ATRA | Atara Biotherapeutics, Inc. | Jun 23, 2022 | 2 | $0 | 4 | Jun 27, 2022 | Director |
RFL | Rafael Holdings, Inc. | Feb 1, 2022 | 1 | $0 | 4 | Apr 12, 2022 | Director |
ATRA | Atara Biotherapeutics, Inc. | Aug 9, 2021 | 1 | $0 | 4 | Aug 10, 2021 | Director |
ATRA | Atara Biotherapeutics, Inc. | Aug 9, 2021 | 0 | $0 | 3 | Aug 10, 2021 | Director |
RFL | Rafael Holdings, Inc. | May 27, 2021 | 1 | $40.6M | 4 | May 28, 2021 | CHIEF EXECUTIVE OFFICER |
RFL | Rafael Holdings, Inc. | May 1, 2021 | 0 | $0 | 3 | May 10, 2021 | CHIEF EXECUTIVE OFFICER |